Exact Therapeutics As · OSL:EXTX
Exact Therapeutics As — CMR Symposium 2024
17 slides from Exact Therapeutics As's conference presentation, Oct 8, 2024
Slide 1: First in Human Study of Acoustic Cluster Therapy with Chemotherapy
First in Human Study of Acoustic Cluster Therapy with Chemotherapy, in patients with Liver Metastases of CRC origin CMR Symposium Oslo, 8 October, 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (the "Presentation") has been prepared by EXACT Therapeutics AS (the "Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’re
Slide 3: Acoustic Cluster Therapy (ACT) – a novel technology for ultrasound mediated oncology therapy
Acoustic Cluster Therapy (ACT®) – a novel technology for ultrasound mediated oncology therapy Technology spin-out from GEHC – focused oncology development strategy: • Clinical proof-of-concept in Phase 1 oncology trial, with encouraging interim results: >10x increase in percent tumour shrinkage vs S
Slide 4: ACT technology defeats biological barriers that hamper drug delivery
The Acoustic Cluster Therapy (ACT®) technology defeats biological barriers that hamper drug delivery • A noninvasive platform to enable targeted, organ-specific drug delivery • ACT treatment is given concomitantly with therapeutics Standard of care therapy Microbubble Microdroplet Ultrasound PS101 i
Slide 5: PS101 – a proprietary ultrasound-activated prodrug
PS101 – a proprietary ultrasound-activated prodrug Commercial scale GMP supply established • PS101 consists of small clusters of gas bubbles and oil droplets • The clusters are free-flowing after injection into the blood and can reach any tissue in the body • Ultrasound exposure converts the oil to
Slide 6: A simple and non-invasive treatment process
A simple and non-invasive treatment process ACT achieves therapeutic benefit through a 2-step ultrasound process Step 1: Activation with high frequency (HF) Step 2: Enhancement with low frequency (LF) › › › HF ultrasound is applied Resulting in phase shift LF ultrasound is applied Oscillation of ACT
Slide 7: Strong preclinical results across cancer models and drugs
Strong preclinical results across cancer models and drugs Mice cancer models, combining different cancer drugs with ACT Pancreas Breast Colon Prostate 5x increase ACT + therapy caused 4x increase ACT + therapy caused in complete the cancer to in complete the cancer to disappearance of completely dis
Slide 8: ACT with irinotecan in colorectal cancer
ACT with irinotecan in colorectal cancer Methods • Human colorectal adenocarcinoma (SW620) xenografts in 20 nude mice – treatment start at approx. 90 mm3 • Therapeutic efficacy of ACT with irinotecan (60 mg/kg i.p.) was 15 Fold growth investigated using 3 treatment sessions on day 0, 7, and 14 10 •
Slide 9: ACTIVATE Phase I study – Innovative assessment of anticancer activity
ACTIVATE Phase I study – Innovative assessment of anticancer activity Patients with liver metastases of colorectal origin • All patients receive standard of care treatment Insonation of • One of the liver tumours is treated with ACT one tumour • Intra-patient comparison of tumour response Tumours (c
Slide 10: Population characteristics – dose escalation
Population characteristics – dose escalation Eight patients enrolled, with a median of 5 prior lines of therapies (range 3-7) 20 ul/kg 40 ul/kg Overall (n=3) (n = 5) (n = 8) Representative scans of patient receiving ACT Age, years, mean (SD) 60 (17) 62 (5) 61 (10) ECOG – 1, n (%) 3 (100%) 5 (100%) 8
Slide 11: ACTIVATE Phase 1 dose-escalation: >10x percent tumour shrinkage compared to control
ACTIVATE Phase 1 dose-escalation: >10x percent tumour shrinkage compared to control lesions • Up to 4 cycles of ACT (3x IV bolus of PS101 + ultrasound) + FOLFOX (5-fluorouracil [5FU], leucovorin, oxaliplatin) or + FOLFIRI (5-FU, leucovorin, irinotecan) • 6 patients evaluable for dose limiting toxici
Slide 12: ACTIVATE Phase 1 – preliminary conclusions
ACTIVATE Phase 1 – preliminary conclusions Data from dose escalation do not show unexpected side effects from PS101 or ultrasound on its own or worsening the effects of chemotherapy In the six evaluable patients in the dose escalation cohort, there was more than 10x increase in average percent t
Slide 13: Pancreatic cancer at a glance
Pancreatic cancer at a glance* Clear unmet medical need • Pancreatic cancer is one of the deadliest cancers • Third most common cancer death • Growing patient population, in particular in younger population groups** • After 5 years, only 12.8% are alive Percentage of Cases by Stage (US) 5-Year Relat
Slide 14: Preclinical Results
Preclinical Results * Pancreatic ductal adenocarcinoma Effect of acoustic cluster therapy (ACT®) combined with chemotherapy in a patient-derived xenograft mouse model** of pancreatic cancer Complete Drug/Combination n Response Rate Nab-paclitaxel + gemcitabine 9 11% Nab-paclitaxel + gemcitabine + AC
Slide 15: ENACT Phase 2 study
ENACT Phase 2 study Locally advanced or borderline resectable pancreatic cancer • Phase 2 study to investigate the efficacy and safety of ACT® in combination with Standard of Care treatment in 1L locally advanced/regional or borderline resectable pancreatic cancer patients • mOS is 10 months w/o sur
Slide 16: Acknowledgements
Acknowledgements The Institute of Cancer Research (ICR) and The Royal Marsden Hospital NHS Foundation Trust • Prof Udai Banerji • Dr Nina Tunariu • Prof Jeff Bamber • Mark O’Leary • Nigel Bush • Sumita Gurung • Wing Yau EXACT Therapeutics • Dr Amir Snapir • Dr Svein Kvåle 16
Slide 17: ACT - defeating barriers in solid tumours
Dr Per Walday CEO M: +47 917 93 429 E: [email protected] ACT® - defeating barriers in solid tumours